Dihexa and Spinogenesis: Why Picomolar Potency Is Both Exciting and Unsettling

What dendritic spines are and why spine density correlates with memory capacity

Memory is stored in patterns of synaptic connection, and synapses are built on physical structures called dendritic spines, tiny protrusions on the dendrites of postsynaptic neurons that contain the receptor clusters and signalling machinery required for synaptic transmission. Spine density, meaning the number of these structures per unit length of dendrite, is not a fixed property of a mature neuron. It changes in response to experience, and those changes are mechanistically tied to learning.

Long-term potentiation (the molecular event that underlies memory encoding) involves both the functional strengthening of existing synapses and the physical growth of new spines. A brain region with higher spine density on relevant dendrites can, in principle, hold more information and form connections more readily. Conversely, spine loss is observed in ageing, in neurodegenerative conditions, and in the early stages of Alzheimer-type pathology, where it correlates with cognitive decline more tightly than amyloid plaque burden does.

This observation gave neuroplasticity researchers a tractable endpoint. If you can measure spine density in hippocampal preparations, you have a quantifiable, biologically meaningful proxy for synaptic capacity. And if you can find compounds that reliably increase spine density, you have a mechanistic basis for claims about memory and cognitive function that goes beyond behavioural assay results alone.

HGF/c-Met signalling — the molecular lever Dihexa pulls

Hepatocyte growth factor, despite its name, is not a liver-specific molecule. HGF and its receptor c-Met are expressed broadly throughout the body, with particularly notable expression in the developing and adult brain. In the central nervous system, HGF/c-Met signalling promotes neuronal survival, axon guidance, and synaptogenesis during development, functions that suggest a legitimate role for this pathway in adult plasticity research.

Dihexa is a hexapeptide derivative of angiotensin IV, engineered at Washington State University to be orally bioavailable, blood-brain-barrier penetrant, and metabolically stable, properties unusual for a peptide compound and the result of deliberate structural optimisation. Its pharmacological identity is as an HGF potentiator: it enhances the binding of HGF to c-Met, amplifying the signalling cascade that follows receptor activation without being an agonist in the conventional sense.

The downstream effects of c-Met activation in neurons include PI3K-Akt pathway stimulation, MAPK-ERK cascade activation, and cytoskeletal reorganisation, exactly the processes required for spine outgrowth and stabilisation. The compound therefore has a mechanistically coherent route from molecular receptor interaction to dendritic spine formation in hippocampal tissue.

Reading the WSU spinogenesis data: what picomolar actually means in a hippocampal slice

The Washington State University research that established Dihexa's cognitive profile used organotypic hippocampal slice cultures, a preparation that preserves the three-dimensional architecture and synaptic connectivity of the hippocampus while allowing precise pharmacological control. In this preparation, the investigators measured spine density after Dihexa treatment across a range of concentrations.

The results were striking. Dihexa produced measurable increases in spine density at picomolar concentrations (that is, concentrations of around 10 to the power of minus 12 molar, one thousand times lower than nanomolar). For context, most pharmacologically active compounds work in the nanomolar to micromolar range. Picomolar potency in a biological assay is exceptional enough to prompt careful re-examination of the methodology before accepting the result. The WSU group's findings, however, have held up in subsequent analyses.

How the potency comparison with BDNF was measured

The potency comparison with BDNF that generated most of the attention requires careful unpacking. BDNF itself can promote spine formation in hippocampal preparations, but at concentrations many orders of magnitude higher than those at which Dihexa produces the same endpoint. The published WSU comparison measured spinogenesis in hippocampal slices for both compounds and reported that Dihexa produced equivalent or greater spine formation effects at concentrations roughly seven orders of magnitude lower than BDNF, making it approximately ten million times more potent on this particular endpoint in this particular preparation.

This comparison does not mean Dihexa is ten million times better at improving cognition than BDNF administration would be. It means that in a controlled cell-culture assay, the spinogenesis endpoint was reached at a dramatically lower concentration. Whether that translates to superior cognitive effects in a living animal, let alone a human, involves translation steps that have not been validated. The WSU spinogenesis mechanism study breakdown provides a detailed account of exactly what the laboratory assay measured and what conclusions it supports.

The c-Met oncology concern — theory versus tested reality

c-Met is one of a family of receptor tyrosine kinases that, when mutated or chronically overactivated, are associated with several cancer types. Amplification of the MET gene and constitutive c-Met activation are found in gastric cancer, non-small-cell lung cancer, and various other solid tumours. This is not a fringe observation — c-Met inhibitors are approved oncology drugs, and the receptor's role in tumour biology is well established.

The concern that follows for Dihexa is obvious: if chronic activation of c-Met signalling is associated with tumour growth, does a compound that potentiates c-Met carry a corresponding oncological risk? This is a legitimate question that cannot currently be answered definitively. The animal studies conducted to date have not reported tumour development as a finding, but they were not designed as carcinogenicity studies, did not use the duration required to detect oncological effects, and did not systematically monitor relevant biomarkers. The absence of a reported tumour signal in short-duration animal studies is reassuring but is not equivalent to demonstrated safety.

The key distinction is between mutation-driven constitutive c-Met activation (a pathological state) and pharmacological potentiation of normal HGF-driven signalling. Whether these are meaningfully different from a tumour-risk standpoint depends on dose, duration, and tissue-specific receptor expression patterns that have not been characterised for Dihexa specifically.

Oral bioavailability in a peptide: why Dihexa's pharmacokinetics are unusual

Most peptide compounds are degraded in the gastrointestinal tract before they can be absorbed systemically, and those that survive are typically excluded from the brain by the blood-brain barrier. Dihexa was specifically engineered to avoid both fates. Its molecular structure confers resistance to gastrointestinal proteases, oral absorption sufficient to produce measurable central effects in animal studies, and blood-brain-barrier penetrance after systemic circulation.

This pharmacokinetic profile sets it apart from most nootropic peptides, which require intranasal or parenteral administration to achieve brain access. Oral bioavailability is a significant practical advantage in research contexts because it allows administration in standard diet or water-vehicle protocols without handling stressed or anaesthetised animals. Whether the same oral bioavailability applies in humans is unknown. The human pharmacokinetics of Dihexa have not been validated in peer-reviewed published work.

Why no human trials exist yet — the regulatory and safety logic

The absence of registered human trials for a compound with this evidence profile might seem surprising, but it follows a straightforward regulatory logic. Before a compound can be studied in humans, it must pass preclinical safety assessment packages that include genotoxicity testing, repeat-dose toxicology in multiple species, and assessment of reproductive toxicity, an investment measured in millions of pounds and several years of development time.

The academic groups that have characterised Dihexa's cognitive and spinogenic properties are not pharmaceutical companies with the infrastructure or funding to initiate clinical development. And no commercial sponsor has yet determined that the compound's profile justifies that investment, partly because the unresolved c-Met safety question would require specific carcinogenicity study designs before a regulatory authority would consider approving human trials. The compound remains strictly preclinical (a research tool for studying HGF/c-Met signalling in cognitive contexts, not a candidate treatment), and that status is likely to persist until the safety question receives a more definitive answer.